Clinical trials: Hep A
Hepatitis C, Chronic
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of co-administration of ABT-450 (also known as paritaprevir) with ritonavir (ABT-450/r) and ABT-267 (also known as ombitasvir) in adults with chronic hepatitis C…
- Trial name
- PEARL-I (NCT01685203)
- Testing
- ABT-450/r, ABT-267, Ribavirin (RBV)
- Volunteers
- 316 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Self Efficacy, Hepatitis C
Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C
The objective is to assess the efficacy, dosing, safety and tolerance of Y- shaped pegylated interferon (YPEG-IFNα-2a) plus ribavirin in Egyptian patients with chronic hepatitis C and with no prior treatment for hepatitis C virus…
- Trial name
- NCT01327729
- Testing
- pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- BioGeneric Pharma
HBe Negative Chronic Hepatitis B, Hepatitis B Viral Infection
ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy
For chronic HBV infection, an optimal pharmacological agent to promote recovery from chronic HBV infection would be one that inhibits HBV DNA polymerase, combined with the clearence from the liver of cccDNA to block HBV…
- Trial name
- NCT00823342
- Testing
- CLEVUDINE IN ASSOCIATION TENOFOVIR
- Where
- France
- Volunteers
- 150 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis C, Chronic, Cirrhosis, Decompensated
Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
There are now several licensed drug treatments for patients with HCV infection. These medications have been shown to be very effective in getting rid of the virus in patients with HCV infection including those with early stages…
- Trial name
- NCT02597166
- Testing
- Ledipasvir/Sofosbuvir
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Hepatitis C
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
The purpose of the study is to determine whether the combination of Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.
- Trial name
- FOURward (NCT02175966)
- Testing
- DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
HCV Coinfection, HIV-1 Infection
Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin
The majority of Human immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) co-infected patients are non responders after 48 weeks of the current standard-of-care with Peg-Interferon/Ribavirin.
- Trial name
- BocepreVIH (NCT01335529)
- Testing
- Boceprevir, Peg-interferon alfa 2b and Ribavirin
- Where
- France
- Volunteers
- 69 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis B, Cirrhosis, Liver
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
- Conditions
- Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
- Trial name
- NCT04588077
- Testing
- Heplisav-B Injectable Product, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mercy Medical Center
COVID-19 Pneumonia, Hypoxemia
Hepatitis B Virus Reactivation in COVID-19
The aim of this observational cohort study was to evaluate adherence to hepatitis B virus (HBV) screening guidelines in a country characterized by low HBV prevalence and assess the potential reactivation and progression of HBV…
- Conditions
- COVID-19 Pneumonia, Hypoxemia, Hepatitis B
- Trial name
- HBV-C19 (NCT07154212)
- Testing
- Hepatitis B virus infection
- Where
- Slovenia
- Volunteers
- 1,793 people
- Sponsor
- University Medical Centre Ljubljana
Hepatitis A
Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines
The primary purpose of this study was to assess whether the protection afforded by Epaxal vaccine co-administered with diphtheria, tetanus, Bordetella pertussis, Haemophilus influenzae type b, and inactivated polio…
- Trial name
- NCT01307436
- Testing
- Epaxal, Havrix 720
- Where
- 2 sites in Israel
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Hepatitis C
Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)
The purpose of this study is to investigate the effectiveness, safety, and tolerability of MK7009 in patients infected with Hepatitis C
- Trial name
- NCT00518622
- Testing
- Comparator: MK7009
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Severe Alcoholic Hepatitis
Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis- Assessment of Impact on Prognosis and Short-term Outcome
Alcoholic liver disease has become one of the foremost causes of chronic liver disease across the world, and a cause of considerable morbidity and mortality.
- Trial name
- NCT03827772
- Testing
- Fecal Microbiota Transplantation, Standard of care treatment
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Hepatitis B, Nonalcoholic Fatty Liver Disease
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).
- Trial name
- NCT02863757
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Humanity and Health Research Centre
Chronic Hepatitis B
A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B
The purpose of this study is to determine whether Adefovir Dipivoxil is effective and safe in treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B for 5 years.
- Trial name
- NCT00857675
- Testing
- AAAA, AAPA, PAAA
- Where
- 10 sites in China
- Volunteers
- 480 people
- Sponsor
- GlaxoSmithKline
Hepatitis B
Seroprevalence of Hepatitis B Infection and Effect of Booster Response Amongst Taiwanese Young Adults
The aim of this study is to observe and evaluate initiate serum anti-HBs titers during entrance health examination among undergraduate freshmen in a university who showed a complete 4-dose HBV vaccination in infancy and whose…
- Trial name
- NCT00702663
- Where
- Taiwan
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Far Eastern Memorial Hospital
Cervical Intraepithelial Neoplasia, Cervical Cancer
Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine
This is a Phase III clinical trial of the novel recombinant HPV 16/18 bivalent vaccine manufactured by Xiamen Innovax Biotech CO., LTD.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT01735006
- Testing
- HPV Vaccine, HEV vaccine
- Where
- China
- Volunteers
- 7,372 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Advanced Hepatocellular Carcinoma
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
PD1 blockade has been approved as salvage therapy for advanced hepatocellular carcinoma (HCC). Although there is not solid evidence that PD1 blockade would induce hepatitis B virus (HBV) reactivation, previous clinical trials of…
- Trial name
- NCT04294498
- Testing
- Durvalumab
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C Recurrence After Liver Transplant
The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
Background: Hepatitis C recurrence, which invariably occurs in viremic liver transplant (LT) recipients, associated with accelerated liver fibrosis leading to established graft cirrhosis in 40-20% of patients in 5 years with…
- Trial name
- NCT01707849
- Testing
- EVL arm, MMF arm
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Hospital Vall d'Hebron
Heart Failure
Hepatitis C Virus (HVC) Positive Heart Grafts in HCV Negative Recipients
To provide proof-of-concept data on the efficacy/safety of transplanting HCV positive donor grafts in HCV negative heart recipients who are currently listed.
- Trial name
- NCT04452578
- Testing
- Procedure: Heart Transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Loma Linda University
Decompensated Hepatitis B Cirrhosis
Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis
Phase I (Single Administration, Randomized, Double-blind, Dose Escalation)Primary Objective: To evaluate the safety and tolerability of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis…
- Trial name
- HBV-DC (NCT07413549)
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells Injection
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Beijing Tuohua Weiye Biotechnology Co., Ltd.
Cirrhosis, Acute Hepatitis
Development of a Predictive Score for the Risk of Infection in the Immediate Post-liver-transplant Period
Liver transplantation (LT) is the only curative treatment option for patients with severe liver disease. Since 2007, the implementation of the MELD score in liver transplant allocation guidelines has led to a change in the…
- Conditions
- Cirrhosis, Acute Hepatitis, Liver, mHLA-DR
- Trial name
- PREDITH (NCT07647978)
- Testing
- blood sampling, Biocollection
- Where
- 3 sites in France
- Volunteers
- 279 people
- Sponsor
- Hospices Civils de Lyon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.